Verana Health and Sight Sciences announce collaboration to conduct research on glaucoma using real-world data from the IRIS Registry

A new research partnership between Verana Health and Sight Sciences aims use data from the IRIS Registry to gain insights that could lead to better results for individuals with from primary open-angle glaucoma (POAG).

Digital health company Verana Health has announced it has joined forces with eyecare technology company Sight Sciences, Inc. to learn more about the real-world outcomes for people with glaucoma. Sight Sciences will utilize Verana Health’s Qdata® Glaucoma real-world data (RWD) module to examine various aspects of its OMNI® Surgical System, a minimally invasive, implant-free glaucoma procedure.

Glaucoma is one of the leading causes of blindness worldwide. In the United States, the most common form of glaucoma is primary open-angle glaucoma (POAG), which affects around 2.7 million Americans. If left untreated, POAG can lead to complete blindness.

Qdata Glaucoma curates data from the Intelligent Research in Sight (IRIS) Registry, one of the largest specialty society clinical data registries from the American Academy of Ophthalmology (Academy). The registry, launched in 2014, collates data from millions of patients and patients visits in the US, complemented with information from more than 60 electronic health records systems and more than 16,000 clinicians and other eye care providers.

With exclusive access to the IRIS Registry, Verana Health provide end-to-end data curation in the form of the Qdata Glaucoma data module, providing comprehensive patient journey information, de-identified patient outcomes data and advanced analytics. Through the collaboration, Sight Sciences will be able to leverage these insights to understand more about the real-world, long-term evidence of glaucoma treatments.

Commenting on the collaboration, Jaime Dickerson, vice president of strategic clinical evidence at Sight Sciences said. “Verana Health shares our conviction that high-quality RWD allows researchers to assess questions such as the long-term efficacy, safety and cost-effectiveness of glaucoma treatments and procedures in the real world.”

Michael Mbagwu, senior medical director for Verana Health continued “Sight Sciences shares our goal of improving outcomes and treatments for people with glaucoma. Their research using RWD from our Qdata Glaucoma module could result in better treatment selections that could help ease the many burdens facing patients with glaucoma and improve their quality of life.”